The Biological Function of DMP-1 in Osteocyte Maturation Is Mediated by Its 57-kDa C-terminal Fragment by Lu, Yongbo et al.
The Biological Function of DMP-1 in Osteocyte
Maturation Is Mediated by Its 57-kDa C-terminal
Fragment
Yongbo Lu,
1 Baozhi Yuan,
2 Chunlin Qin,
1 Zhengguo Cao,
1 Yixia Xie,
1 Sarah L Dallas,
3 Marc D McKee,
4
Marc K Drezner,
2 Lynda F Bonewald,
3 and Jian Q Feng
1
1Department of Biomedical Sciences, Baylor College of Dentistry, Texas A&M Health Science Center, Dallas, TX, USA
2Department of Medicine, University of Wisconsin and GRECC, William F. Middleton Veterans Administration Hospital, Madison, WI, USA
3Department of Oral Biology, University of Missouri–Kansas City, Kansas City, MO, USA
4Faculty of Dentistry and Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada
ABSTRACT
Dentinmatrixprotein1(DMP-1)isakeymoleculeincontrolling osteocyteformation andphosphatehomeostasis. Basedonobservations
that full-length DMP-1 is not found in bone, but only cleaved fragments of 37 and 57kDa are present, and in view of the finding that
mutations in the 57-kDa fragment result in disease, we hypothesized that the 57-kDa C-terminal fragment is the functional domain of
DMP-1. To test this hypothesis, a 3.6-kb type I collagen promoter was used to express this 57-kDa C-terminal fragment for comparison
with full-length DMP-1 in Dmp1 null osteoblasts/osteocytes. Not only did expression of the full-length DMP-1 in bone cells fully rescue
the skeletal abnormalities of Dmp1 null mice, but the 57-kDa fragment also had similar results. This included rescue of growth plate
defects, osteomalacia, abnormal osteocyte maturation, and the abnormal osteocyte lacunocanalicular system. In addition, the abnormal
fibroblast growth factor 23 (FGF-23) expression in osteocytes, elevated circulating FGF-23 levels, and hypophosphatemia were rescued.
These results show that the 57-kDa C-terminal fragment is the functional domain of DMP-1 that controls osteocyte maturation and
phosphate metabolism.  2011 American Society for Bone and Mineral Research.
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Introduction
D
entin matrix protein 1 (DMP-1) is expressed predominantly
in odontoblasts in tooth and osteocytes in bone.
(1–3)
Deletion of murine Dmp1 causes striking defects in tooth and
bone during postnatal development in C57/B6 or CD-1 back-
ground mice.
(4,5) Recently, we and others have demonstrated
that DMP1 mutations result in autosomal recessive hypopho-
sphatemic rickets (ARHR) in humans similar to the phenotype of
Dmp1nullmice.Thisconditionischaracterizedbyrickets andthe
presenceof large amounts of osteoid inbone (osteomalacia) and
is accompanied by elevated circulating fibroblast growth factor
23 (FGF-23).
(6–9) Using the Dmp1 null mouse as a model for
human ARHR, we found that Dmp1 null osteocytes express
elevated FGF-23, suggesting that Dmp1 might be a negative
regulator of FGF-23 expression during bone development.
(6)
FGF-23 is a potent phosphaturic hormone expressed
predominantly by osteocytes in bone
(6,10–12) that target
the kidney to promote renal excretion of phosphate.
(13,14) In
addition, PHEX (phosphate-regulating gene with homologies to
endopeptidases on the X chromosome) also has been shown to
regulate FGF-23 expression in bone.
(12) PHEX is predominantly
expressed in osteoblasts and osteocytes.
(15) PHEX mutations in
mice and humans result in autosomal dominant hypopho-
sphatemic rickets (ADHR), accompanied by elevated circulating
FGF-23,aphenotype similartothat ofDmp1null mice.
(6,10) Taken
together, these observations suggest that elevated circulating
FGF-23 and hypophosphatemia are pathogenic factors involved
in both Phex and Dmp1 mutant mice.
We have previously identified two proteolytic fragments of
DMP1, a 37-kDa N-terminal fragment and a 57-kDa C-terminal
fragment, but little intact protein from rat long bone and dentin
extracts.
(16,17) The 57-kDa fragment is highly phosphorylated,
containing 41 phosphates,
(16) whereas the 37-kDa fragement
was shown to be a proteoglycan with a chondroitin sulfate chain
attached via Ser74.
(18) These findings lead to the hypothesis that
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331the full-length DMP-1 might represent an inactive precursor that
has to be cleaved to become functional.
(16) Studies using an in
vitro cell-free system have indicated that full-length DMP-1, its
two fragments, and the extent of their phosphorylation have
distinct effects on biomineralization.
(19) Specifically, the highly
phosphorylated 57-kDa fragment likely functions as a hydro-
xyapatite nucleator.
(19)
In addition, it was discovered that a DMP1 mutation, which
results in replacement of the last 18 amino acid residues with 33
novel residues, results in ARHR.
(6,7) In vitro studies showed that
this mutant DMP-1 is secreted and processed into the 37-kDa
N-terminal fragment and the mutant 57-kDa fragment,
(6)
suggesting that patients should have normal 37-kDa fragment
expression. These observations suggest that the 57-kDa
fragment might be the key functional domain of DMP-1.
Wehavepreviouslygeneratedtwoseparatetransgeniclinesof
mice expressing the full-length and the 57-kDa fragment under
thecontrol ofa3.6-kbtypeIcollagenpromoter.
(20)ThemRNAsof
bothtransgenesarehighlyexpressedinosteoblasts,whereasthe
proteins of these transgenes are distributed predominantly in
the matrix surrounding osteoblasts and osteocytes.
(20) Further,
mice carrying either transgene do not exhibit an apparent
skeletal phenotype.
(20) By crossing these transgenes onto the
Dmp1 null background, this study investigated which aspects of
the Dmp1 null skeletal phenotype could be rescued by the full-
length and 57-kDa DMP-1 fragment in order to further
understand the function of DMP-1 in the skeleton. Our study
shows that the 57-kDa fragment recapitulates the function of
full-length DMP-1 in regulation of mineralization and osteocyte
maturation and highlights the molecular mechanisms respon-
sible for hypophosphatemic rickets.
Materials and Methods
Mice
Dmp1 knockout (KO) mice with a C57B/L6 genetic background
have been described previously.
(21) Transgenic mice over-
expressing full-length DMP-1 were generated on a CD-1 genetic
background,
(22) and the 57-kDa C-terminal fragment transgenic
mice were generated on a C57B/L6 genetic background as
described previously.
(20)To determine thefunction ofthe 57-kDa
C-terminal fragment or the full-length of DMP-1 in vivo, these
transgenes were introduced into the Dmp1 null background by
breeding the transgenic mice with Dmp1 null mice separately.
The mice were fed with autoclaved Purina rodent chow (5010,
Ralston Purina, St. Louis, MO, USA) containing 1% calcium, 0.67%
phosphorus, and 4.4 IU of vitamin D/g. All animal protocols were
approved by the Institutional Animal Care and Use Committee.
Quantitative real-time PCR analysis
Total RNA was extracted from 10-day-old mouse bones using
Trizol reagent (Invitrogen, San Diego, CA, USA) according to the
manufacturer’s protocol. One microgram of total RNA then was
treated with Turbo DNase (Ambion, Austin, TX, USA) and reverse
transcribed into first-strand cDNA using a high-capacity cDNA
reverse-transcription kit (Invitrogen). Quantitative real-time PCR
was performed using SYBR Green PCR mix plus gene-specific
primers in a 7700 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA). PCR conditions were as
follows: 40 cycles of 958C for 15seconds, 608C for 30seconds,
and 728C for 30seconds. For each gene, three independent PCRs
from the same reverse-transcription sample were performed.
The presence of a single specific PCR product was verified by
melting-curve analysis, confirmed on an agarose gel, and further
sequenced by the Applied Biosystems sequencing system
(Applied Biosystems). Genes were analyzed including osteocalcin
(OCN), alkaline phosphatase (ALP), MEPE, and sFRP4. GAPDH was
used as an internal control. The primer sequences used are OCN
forward primer (F), 5’’-CTC TGT CTC TCT GAC CTC ACA G-3’’, and
reverse primer, 5’V-GGA GCT GCT GTG ACA TCC ATA C-3’’; ALP
forward primer, 5’-CTT GCT GGT GGA AGG AGG CAG G-3’’, and
reverse primer, 5’’-CAC GTC TTC TCC ACC GTG GGT C-3’’; MEPE
forward primer: 5’’-TGT TGG ACT GCT CCT CTT CA-3’’, and reverse
primer, 5’’-TCC TTC CCT CCG TAGTTC G-3’’; sFRP4forward primer,
5’’-GTG CAA GTG CAA AAA GGT GA-3’’, and reverse primer, 5’’-
ATC ATC CTT GAA CGC CAC TC-3’’; and GAPDH forward primer,
5’’-GGT GTG AAC CAC GAG AAA-3’’, and reverse primer, 5’’-TGA
AGT CGC AGG AGA CAA-3’’.
Fluorochrome labeling of the mineralization front
To visualize bone mineralization in mice, double fluorescence
labeling was performed as described previously.
(22) Briefly, mice
were first injected intraperitoneally with calcein green (5mg/kg),
followed by injection of an alizarin red label (5mg/kg i.p.; Sigma-
Aldrich, St Louis, MO, USA) 5 days later. Mice were euthanized
48hours after injection of the second label, and the bones were
removed and fixed in 70% ethanol for 48hours. The specimens
were dehydrated through a graded series of ethanol (70% to
100%) and embedded in methyl methacrylate (MMA) without
prior decalcification. The 50-mm nondecalcified samples from
these animals were photographed using a Nikon PCM-2000
confocal microscope coupled with an Eclipse E-800 upright
microscope (Nikon Instruments, Melville, NY, USA) for fluor-
ochrome labeling or in combination with 4,6-diamidino-2-
phenylindole (DAPI) staining of nuclei of osteocytes.
Visualization of the lacunocanalicular system by
procion red
This smallmolecular dyewasinjectedthrough thetailvein(0.8%,
0.01mL/g) under anesthesia with 2,2,2-Tribromoethanol (5mg/
kg of body weight) 10minutes before euthanization. The fresh
bone was fixed in 70% EtOH and sectioned at 50mm thickness
using a Leitz 1600 saw microtome (Ernst. Leitz Wetzlar GmbH,
Wetzlar, Germany). Sections were imaged using a Nikon C100
confocal microscope with an optronics cooled CCD (charge-
coupled device) camera.
Scanning electron microscopy (SEM) and transmission
electron microscopy (TEM)
To image the osteocyte lacunocanalicular system, SEM of resin-
casted bone samples was performed. Bone tissues were fixed in
70% ethanol and embedded in MMA (Buehler, Lake Bluff, IL,
USA). The surface of the MMA-embedded bone was polished,
followed by acid etching with 37% phosphoric acid for 2 to
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with gold and palladium. Samples were examined by an FEI/
Philips XL30 field emission environmental SEM (Phillips,
Hillsboro, OR, USA). For TEM, specimens were fixed with 4%
paraformaldehyde and 1% glutaraldehyde in 0.1M sodium
cacodylate buffer (pH 7.2), then postfixed with 1% osmium
tetroxide in 0.1M sodium cacodylate buffer, and processed for
embedding in LR White acrylic resin (London Resin Company,
Bershire, UK). Colloidal-gold immunostaining of DMP-1 was
performed and examined by TEM using a JEOL 2000FXII
transmission electron microscope (Jeol Ltd., Tokyo, Japan) as
described previously.
(22)
Radiography and micro–computed tomography (mCT)
The long bones or vertebrae were dissected and X-rayed using a
Faxitron radiographic inspection unit (Model 8050-020, Field
Emission Corporation, Inc., McMinnville, OR, USA) with digital
image capture capabilities. The long bones, vertebrae, and
metatarsals were scanned in a mCT imaging system (35, Scanco
Medical, Bassersdorf, Switzerland) as described previously.
(4,5)
Histology
For paraffin block preparations, specimens were fixed in freshly
prepared 4% paraformaldehyde in PBS (pH 7.4), decalcified, and
embedded in paraffin by standard histological procedures, as
described previously.
(3) Then 5-mm sections were cut and dried.
Sections were used for Safranin-O staining, immunohistochem-
istry, TRAP staining, and in situ hybridization using digoxigenin-
labeled antisense RNA (cRNA) probes as described previously.
(6)
For undecalcified bones, specimens were embedded in MMA
and cut at 6-mm thickness using a Leica 2165 rotary microtome
(Ernst. Leitz Wetzlar GmbH). Undecalcified sections were stained
by von Kossa staining,
(21) Goldner’s Masson trichrome staining.
(6)
alizarin red/alcian blue staining,
(21) and alkaline phosphatase
(ALP) cytochemistry.
(23)
Serum biochemistry
Serum calcium, phosphorus, and FGF-23 levels were determined
as described previously.
(6) Briefly, serum calcium content was
analyzed using a colorimetric calcium kit (Stanbio Laboratory,
Boerne, TX, USA). Serum phosphorus was measured by the
phosphomolybdate–ascorbic acid method. Serum FGF-23 level
was determined by a full-length FGF-23 ELISA kit (Kainos
Laboratories, Tokyo, Japan).
Statistical analysis
Data analysis was performed with Student’s t tests for two-group
comparison and with one-way ANOVA for multiple-group
comparisons. If significant differences were found with one-
way ANOVA, the Bonferroni method was used to determine
which groups were significantly different from others. The
quantified results are represented as the standard error of the
mean (SEM). p<.05 was considered statistically significant.
Fig. 1. Reexpression patterns of full-length DMP-1 in Dmp1 null (KO)
mice driven by the 3.6-kb murine Col1a1 promoter. DMP-1 expression in
Dmp1 heterozygous (HET) control mice (left panels), Dmp1 null mice
(middle panels), and Col1a1 full-length DMP-1 in the Dmp1 null back-
ground(RES, right panels) was analyzedin tibias from 4-week-old mice by
in situ hybridization (a, signal in red color), immunohistochemistry (b,
signal in brown color), and immunogold labeling and transmission
electron microscopy (c). The assays showed that expression of endogen-
ous DMP-1 in HET mice was found predominantly in the osteocytes (Oyc,
black arrows) embedded in the bone matrix. No expression of endogen-
ous DMP-1 was detected in Dmp1 null mice. Note that in situ hybridiza-
tion showed that the transgene was highly expressed in osteoblasts (Ob,
black arrows) but that the protein is present in both osteoblasts and
osteocytes. Immunogold staining showed that the endogenous DMP-1
protein was localized to the lamina limitans at the edges of the canaliculi
in the bone matrix in HET mice. As expected,there was no DMP-1 protein
present in the Dmp1 null mouse bone (middle panels in a, b, and c).
However, the transgenic DMP-1 protein was localized predominantly
in both the osteoblast layer and in lamellae closely adjacent to the
osteocytes (RES). Note that in d, the endogenous Dmp1 mRNA was
weakly expressed in chondrocytes (left panel), but the transgenic
Dmp1 mRNA was not detected in chondrocytes (right panel).
IDENTIFICATION OF DMP-1 FUNCTIONAL DOMAIN Journal of Bone and Mineral Research 333Results
Targeted expression of DMP-1 in osteoblasts/osteocytes
but not in chondrocytes
Although DMP-1 is highly expressed in osteocytes,
(24) DMP-1 is
also expressed toa much lower extent in osteoblasts, particularly
during embryonic development.
(21,25) To better understand the
functions of DMP-1 in bone, the murine 3.6-kb Col1a1 promoter
was used to drive Dmp1 transgenes. Figure 1A shows that the
full-length Dmp1 mRNA was targeted to osteoblasts, but the
protein was highly expressed in both osteoblasts and osteocytes
to a much higher level than endogenous DMP-1 (Fig. 1B, right
panel). Importantly, immunogold TEM data showed the same
distribution pattern of both transgenic and endogenous DMP-1
protein in the lamina limitans of the extracellular matrix
immediately surrounding osteocyte processes in the HET control
mice, no DMP-1 in the Dmp1 null mice, and restoration of DMP-1
protein in Dmp1 null osteocytes (Fig. 1C). By in situ hybridization,
note that DMP-1 is weakly expressed in chondrocytes, but there
was nosignal inDmp1 null orthe rescued chondrocytes (Fig. 1D).
Reexpression of full-length DMP-1 rescued the skeletal
abnormalities of Dmp1 null mice
The full-length Dmp1 transgene was introduced into the Dmp1
null background mice by crossing full-length Dmp1 transgenic
mice with Dmp1 null mice. Multiple evaluations then were used
to examine whether reexpression of the full-length DMP-1 could
rescue the Dmp1 null phenotype.
At day 10, ossification in Dmp1 null epiphyses was largely
undetectable by mCT (arrow in Fig. 2A, left panel), but the Dmp1
null epiphyses were partially restored when full-length DMP-1
wasreexpressed inbone.Second, theporousnatureoftheDmp1
null and expanded metaphyses was fully rescued, as documen-
ted by both representative mCT images and quantified data
(Fig. 2A, right and lower panels). Note that at the age of 5 weeks,
the Dmp1 null epiphysis and the bone length were fully rescued
by the full-length DMP-1 (Fig. 2B). This result indicates that there
is a delay in the rescue of Dmp1 null epiphysis phenotype at an
early stage, but this phenotype is fully rescued at 5 weeks of age.
Reexpression of full-length DMP-1 rescued mineralization
abnormalities of Dmp1 null mice
One of the key defects in Dmp1 null mice is defective
mineralization.
(4,6) Using a fluorochrome labeling technique,
three discrete label lines were observed in both the control and
rescued mice in contrast to the Dmp1 null mice (Fig. 3A).
Similarly, the images combining fluorochrome labeling with
DAPInuclearstaining,usedtovisualizethepositionofosteocytes
relative to mineralization fronts, showed a complete rescue by
the full-length DMP-1 (Fig. 3B). The von Kossa stain, a common
staining protocol used for detection of mineralization defects,
showed a complete rescue of the osteomalacia in Dmp1 null
micebythefull-lengthDmp1transgene(Fig.3C).Takentogether,
these results demonstrate that the full-length DMP-1 completely
rescues mineralization defects observed in Dmp1 null long bone.
Reexpression of full-length DMP-1 rescued the defects
in the osteocyte lacunocanalicular network and in the
growth plate
Osteocytes and their dendrites are located in the porosities in
bone, the lacunocanalicular network. In Dmp1-HET control mice,
this system is revealed by the fluorescent images of bone
sections after injection of a small molecular dye, procion red
(Fig. 4A, left panel), and the smooth walls of the lacunae and
canaliculi by SEM of acid-etched, resin-casted bone samples
(Fig. 4B, left panel). These methods also documented the
abnormal lacunocanalicular system in Dmp1 knockout (KO) bone
Fig. 2. Rescue of Dmp1 null bone abnormalities with the full-length
Dmp1 transgene at the ages of 10 days and 5 weeks. (A) Representative
mCT images of tibias from the HET, KO, and rescued mice (RES) at the age
of 10 days. The whole-mount view is shown in the left panel, the sagittal
sections of metaphyses are shown in the middle panel, and the cross
sections of midshaft are shown in the right panel; the quantified data
are shown in the lower panels. (Data are mean SEM; n¼4;
   p<.001).
(B) Whole-mount views of 5-week-old tibias from the HET, KO, and
rescued (RES) mice are shown in the left panel; the quantified data
are shown in the right panel. (Data are mean SEM; n¼4;
   p<.001).
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osteocyte lacunae with rough, not smooth, lacunar walls (Fig. 4A,
B, middle panels), which was completely rescued by reexpression
of full-length DMP-1 (Fig. 4A, B, right panels). Taken together,
these observations support a direct role of DMP-1 in maintaining
the osteocyte lacunocanalicular system.
Even though DMP-1 is weakly expressed in chondrocytes
(Fig.1D),
(26)theDmp1nullricketsphenotypeislikelyattributableto
hypophosphatemia.
(6) Here we show that the hypertrophic
chondrocyte zone in Dmp1 null mice is remarkably expanded
withfewchangesinothergrowthplatezonesattheageof10days,
as revealed by Safranin O staining (Fig. 4C, upper middle panel). At
the age of 7 weeks, the Dmp1 null growth plate lost its continuity
a n df o r m e dm u l t i p l ec h o n d r o g e n i cc l u s t e r so fd i f f e r e n ts i z e s
(Fig. 4C, lower middle panel). Reexpression of full-length DMP-1
rescuedessentiallyallthesedefectsintheDmp1 null growth plates
(Fig. 4C, right panels), which are identical to the age-matched
controls (Fig. 4C, left panels). These data support an indirect role of
DMP-1 in chondrogenesis because the DMP1 transgene is not
expressed in chondrocytes (Fig. 1D)
Fig. 3. Rescue of Dmp1 null bone defects in mineralization with the full-
lengthDmp1 transgene. (A) The doublefluorochrome labels displayedan
identicalbone-formationrateinHET(leftpanel)andRES(rightpanel)mice
in contrast to the diffuse label in KO mice (middle panel) at 2 months of
age. Diffuse fluorochrome labels in the Dmp1 null mice (middle panel)
were fully restored in the rescue group (right panel). (B) Confocal micro-
scopic images of fluorochrome labeling, counterstained with DAPI for
visualization of osteocyte nuclei (blue, white arrows), showed that osteo-
cytes are separatedfrom the mineralization front in HET control mice (left
panel) and RES mice (right panel). Diffuse fluorochrome labeling in the
Dmp1 null mice (middle panel) was replaced with sharp lines in the RES
group (right panel). (C) von Kossa staining showed restored mineraliza-
tion in the RES mice, whereas abundant osteoid (red color, arrows) was
present in the KO tibias at the age of 2 months.
Fig. 4. Rescue of the malformed osteocyte lacunocanalicular network
and growth plate defects. (A) Visualization of the disorganized osteocyte
canalicular system in 7-week-old Dmp1 null mice (middle panel) with
procion red injection compared with the well-organized control osteo-
cytes (left panel) and the rescued osteocytes (right panel) using confocal
microscopy at 565-nm excitation and 610-nm emission. (B) SEM images
of the acid-etched, resin-casted osteocyte canalicular system from the 7-
week-old HET control mice(left panel), the Dmp1null mice (middlepanel),
and the rescued mice(right panel). Note that the poorly formed osteocyte
canalicular system in Dmp1 null mice was fully rescued by the full-length
Dmp1 transgene. (C) Safranin-O staining of the tibia growth plate,
showing that Dmp1 null mice displayed about a threefold increase in
the hypertrophic zone at the age of 10 days and formation of multiple
chondrocyte clusters with a loss of continuity at 7 weeks of age (middle
panels).Allthesemorphologicalchangeswerecompletelyrescuedby the
full-length Dmp1 transgene in the Dmp1 null background (right panels)
compared with the HET controls (left panels).
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expression profile of the Dmp1 null bone
Our previous study
(6) has shown that Dmp1 null osteoblasts/
osteocytes have altered functions. The osteocytes continuously
express some osteoblast/early osteocyte–related genes, such as
type I collagen (a marker for osteoblasts), E11/gp38 (a marker
for early osteocytes), and FGF-23, and fail to differentiate into
mature osteocytes. In this study, we screened 13 molecular
markers, including Osx (osterix, a transcriptional factor essential
for bone formation, mainly expressed in osteoblasts), Phex (its
mutations lead to a phenotype very similar to that seen with
Dmp1 mutations), E-11/gp38, MEPE (matrix extracellular phos-
phoglycoprotein, expressed in both osteoblasts and osteocytes),
and FGF23 (Fig. 5) as well as five common osteoblast markers,
osteocalcin (OC), bone sialoprotein (BSP), osteopontin (OPN),
biglycan, and Col I (type I collagen) in two long bone sites:
cortical bone and trabecular bone (Supplemental Fig S1). All
these markers were increased dramatically in Dmp1 null
osteocytes (Fig. 5 and Supplemental Fig. S1, middle panels),
and reexpression of full-length DMP-1 restored their normal
expression patterns (Fig. 5 and Supplemental Fig. S1, right
panels), suggesting that the delay in osteocyte maturation was
rescued. This in vivo rescue confirms that DMP-1 is essential for
osteocyte maturation and normal bone mineralization. The full-
length DMP reexpression model serves as an ideal control for
determining the in vivo biological function of the 57-kDa C-
terminal fragment.
The 57-kDa C-terminal fragment of DMP-1 restores the
Dmp1 KO phenotype to normal
Having established that reexpression of full-length DMP-1
rescued the skeletal abnormalities of Dmp1 null mice, we next
examinedtheinvivofunctionofthe57-kDaC-terminalfragment.
Using the same strategy, the 57-kDa fragment was reexpressed
in Dmp1 null osteoblasts/osteocytes by crossing Col1a1-57K
transgenic mice with Dmp1 null mice. Western blotting analysis
confirmed reexpression ofthe 57-kDa C-terminal fragment in the
Dmp1 KO bones (Fig. 6A). Similar to the full-length DMP-1,
targeted reexpression of the 57-kDa C-terminal fragment in the
Dmp1 null mice rescued the bone morphology (Fig. 6B), the
serum levels of FGF-23 (Fig. 6C, upper panel), Pi (Fig. 6C, middle
panel), and Ca (Fig. 6C, lower panel), the bone-formation rate
(Fig. 6D, right panel) as well as the key markers such as sclerostin
(Fig. 6E, right panel), type I collagen (Fig. 6F, right panel), and FGF-
23 (Fig. 6G, right panel). Finally, quantitative real-time PCR
analysis showed that OCN, ALP, MEPE, and sFRP-4 are elevated in
Dmp1 KO mice and that their expression levels were restored to
the control levels by reexpression of the 57-kDa C-terminal
fragment (Table 1).
Taken together, these data show that the DMP-1 57-kDa C-
terminal fragment possesses the biological function of the intact
protein to promote osteocyte maturation and maintenance of
phosphate homeostasis.
Discussion
DMP-1, an extracellular matrix protein highly expressed in
osteocytes, isprocessed intoa37-kDaN-terminalfragment anda
57-kDa C-terminal fragment
(16); however, it was not known
which fragment is essential for DMP-1 function. In this study we
used targeted reexpression of full-length DMP-1 or its 57-kDa
C-terminal fragment in Dmp1 null osteoblasts/osteocytes to
investigate the specific roles of the C-terminal fragment relative
to the full-length DMP-1 in vivo. Our data show that both
transgenes fully rescue the skeletal abnormalities of Dmp1 null
Fig. 5. Targeted expression of DMP-1 rescued the gene expression
patterns in the Dmp1 null cortical bone. In situ hybridization (A, Osx,
osterix; B, Phex, phosphate-regulating gene with homologies to endo-
peptidases on the X chromosome; D, MEPE, matrix extracellular phos-
phoglycoprotein; E, Fgf23, fibroblast growth factor 23) and
immunohistochemistry (C, E11) assays were performed on the HET
control tibias (left panels), the Dmp1 null tibias (middle panels), and
the RES (right panels) tibias at the age of 10 days. All these genes in
Dmp1 null cortical bone were increased (mainly in osteocytes) and were
restored to control levels by targeted expression of the full-length Dmp1.
Signal in dark purple color (A, B), in browncolor (C), and in red color (D, E).
336 Journal of Bone and Mineral Research LU ET AL.Fig. 6. Targetedexpressionofthefull-lengthDMP-1orthe57-kDC-terminalfragmentinDmp1KOmicerescuedtheskeletalabnormalities,serumFGF-23,
Pi homeostasis, and malformed osteocyte lacunocanalicular network. (A) Western blot data obtained from HET, KO, and rescued long bones documenting
expressionofthe57-kDafragmentin2-month-oldDmp1KO mice.(B)mCTimagesshowingsimilarrestorationofthemorphologyofthefemurbytargeted
expression ofeitherthefull-lengthDMP-1orthe57-kDafragmentin theDmp1KO backgroundat 7 weeksofage.(C) RestorationofserumlevelsofFGF-23
(upper panel), Pi (phosphorus, middle panel), and Ca (calcium, lower panel) to normal levels in both the full-length and the 57-kDa rescued mice at 7 weeks
of age; Data are mean SEM; n¼4t o6 ;
  p<.01;
   p<.001. (D) The double fluorochrome labels showed a similar bone-formation rate in HET mice (left
panel) and the 57-kDa RES mice (right panel) in contrast to the diffuse label in the KO mice (middle panel) at 7 weeks of age. Immunohistochemistry (E,
sclerostin) and in situ hybridization (F, type I collagen; G, FGF-23) assays were performed on HET control tibias (left panels), Dmp1 KO tibias (middle panels),
and the 57-kDa RES tibias (right panels) at the age of 10 days. Sclerostin, a marker for mature osteocytes, in Dmp1 KO osteocytes was largely undetectable,
whereas ColI and Fgf23 mRNAs were increased dramatically in the Dmp1 KO osteocytes. All these changes were restored to control levels by targeted
expression of the 57-kDa C-terminal fragment. Signal in brown color (E) and in red color (F,G).
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and hypophosphatemia. These results support the hypothesis
that the 57-kDa C-terminal fragment is responsible for the
biological function of DMP-1 in maintaining phosphate home-
ostasis through controlling Fgf23 expression in bone. In addition,
our study supports the concept that DMP-1 controls osteocyte
maturation through downregulation of many osteoblast-specific
genes, such as Osx and Col1, as well as upregulation of the
osteocyte-specific gene (Sost).
The 57-kDa C-terminal fragment is the biologically
functional domain of DMP-1
We reported previously that DMP-1 was cleaved into a 37-kDa N-
terminal fragment and a 57-kDa C-terminal fragment found in the
extracellular matrix of bone and dentin.
(16) This suggests that full-
length DMP-1 may not be an active molecule but is most likely an
inactive precursor.
(27) The enzyme responsible for processing
DMP-1 was identified subsequently as bone morphogenetic
protein 1 (BMP-1)/tolloid-like metalloproteinase.
(28) This group of
enzymesisnottissue-specificbecausetheyarewidelyexpressedin
many mesenchymally derived tissues and have been shown to
cleave several other protein precursors, including those of several
collagens (types I, II, III, V, VII, and VI), biglycan, and lysyl oxidase at
selected X-Asp bonds.
(24)
Mutations identified in the human DMP1 gene that are
responsible for ARHR phenotype include (1) p.M1V, (2)
c.1483del1490, removing the last 18 amino acid residues, and
(3) deletion of 49kb between DMP1 exon 3 to an intergenic
region5’tointegrin-bindingsialoprotein.
(6,9,29)Thefirstmissense
mutation of the signal peptide results in abnormal targeting to
the cytoplasm, and the third mutation is a functionally null allele
with no DMP-1 expression. Interestingly, protein transcribed
from the second mutation, c.1483del1490, where the C-terminal
18 amino acid residues are replaced with 33 novel amino acid
residues, can be transported properly to the trans-Golgi network
and is processed properly to produce a normal 37-kDa N-
terminalfragmentbutamutant57-kDaC-terminalfragment.The
fact that these patients have an ARHR phenotype underscores
the importance of the C-terminal portion of the molecule in
DMP-1 function. Together, these human genetic studies and our
in vivo data support the conclusion that the 57-kDa fragment is
the functional domain of DMP-1.
The normal 57-kDa fragment also contains the RGD (Arginine-
Glycine-Aspartic Acid) integrin-binding sequence,
(30) a nuclear
localizationsequence,
(31)andtheminhibinASARM(acidicserine-
and aspartate-rich motif) peptide shown to inhibit mineraliza-
tion.
(32,33) Therefore, future studies are needed to determine the
contributions of these functional domains to the biological
activity of DMP-1 and to further refine the functional domains of
the 57-kDa fragment. These findings could aid in the develop-
ment of synthetic peptides or small molecules mimicking DMP-1
for the treatment of bone diseases such as hypophosphatemic
rickets. At this time, the role of the 37-kDa fragment in bone
biology is not clear and remains to be tested in vivo.
Similar to the Dmp1 KO phenotype, an identical phenotype
has been observed in Hyp mice, which carry mutations in the
Phex gene, as well as in patients with PHEX mutations. The
overlap in phenotypes with PHEX and DMP1 loss of function,
together with the full rescue of the Dmp1 null phenotype by the
57-kDa C-terminal fragment, is suggestive that DMP-1 may be
processed by PHEX. However, studies from our lab as well as
others do not support such a role for PHEX.
(7,20) It is also of note
that the expression of DMP-1 does not appear to be altered in
Hyp mice (data not shown). More interestingly, in contrast to the
full rescue of the Dmp1 KO phenotype by DMP-1 reexpression,
the targeted reexpression of Phex in Hyp mice failed to rescue
most of the phenotype, as reported by three independent
research groups.
(34–36) The promoters that have been used to
drive the wild-type Phex gene include osteocalcin, the 2.3-kb
Col1A1, two bone-specific promoters, and the ubiquitous human
b-actin promoter.
(34–36) Although the underlying reason is
unknown, it has been suggested that the mutated PHEX protein
acts in a dominant-negative manner and interferes with the
function of the native protein. Future studies are needed to
further elucidate the relationship of DMP-1 and PHEX in
regulation of FGF-23 and phosphate homeostasis.
DMP has no direct role in the growth plate
We have shown previously that deletion of Dmp1 led to severe
growth plate defects, which were thought to be due to a
reduction in apoptosis in chondrogenesis.
(4) A high-phosphate
diet improved the defects dramatically in the growth plate of
Dmp1 null mice,
(6) suggesting an indirect effect of DMP-1 on the
growth plate through phosphate regulation. Interestingly,
Maciejewska and colleagues
(37) showed that DMP-1 is indeed
expressed in chondrocytes, suggesting that DMP-1 may have
both direct and indirect roles in control of chondrogenesis. To
better address this issue, we used the 3.6-kb Col1a1 promoter to
target the Dmp1 transgene only in bone but not cartilage. Our in
situhybridizationdataconfirmedthattherewasnoexpressionof
the transgene in the cartilage. However, the Dmp1 null growth
platephenotypewasfullyrescued,whichisinagreementwithan
Table 1. Quantitative Analysis of the Expression of Bone Marker Genes in Various Genotypes
Full length DMP1 57 KD
Gene HET KO RES p value HET KO RES p value
OCN 1.12 0.25 3.167 0.29 0.797 0.175 <0.05 1.016 0.095 1.827 0.29 1.089 0.202 <0.05
ALP 1.038 0.143 2.21 0.215 1.146 0.29 <0.05 1.091 0.245 1.813 0.179 0.757 0.116 <0.05
MEPE 1.038 0.135 7.37 4.3 0.58 0.26 <0.05 1.025 0.129 2.745 0.5 0.96 0.167 <0.05
sFRP-4 1.02 0.232 5.356 2.23 1.545 0.41 <0.05 1.04 0.2 1.567 0.335 0.579 0.115 <0.05
Data shown are means SEM from four 10-day-old mice. Data analyzed by One-way ANOVA.
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expression in bone to regulate phosphate homeostasis.
(6) Thus
we conclude that the Dmp1 null growth plate phenotype is
attributable to hypophosphatemia.
DMP is a key molecule that controls osteocyte maturation
Unlike maturation and matrix production by osteoblasts
characterized by increases in gene expression and cell metabolic
activity, there is a dramatic decrease in gene expression and
metabolic activity during maturation of osteocytes. Our previous
studies
(6) and current findings suggest that DMP-1 is an ideal
molecule to control osteocyte maturation. The supporting
evidence includes (1) DMP-1 is highly expressed in osteocytes
with a very low level of expression in osteoblasts, (2) Dmp1 null
mice display significant pathological changes in the osteocyte
lacunocanalicular system, (3) many genes expressed in normal
osteoblasts either remained active in Dmp1 null osteocytes (such
as type I collagen or BSP) or were ectopically produced (such as
FGF-23 and osteocalcin), and (4) the preceding abnormalities are
rescuedbytargeted expressionofeitherthe full-lengthofDMP-1
or the 57-kDa fragment.
Taken together, we propose the following working model for
DMP-1 (Fig. 7). DMP-1 is processed into a 37-kDa N-terminal
fragment and a 57-kDa C-terminal fragment by BMP-1 or a
subtilisin-like proprotein convertase.
(16,20,28) The 57-kDa C-
terminal fragment is the functional domain ofDMP-1, controlling
osteocyte maturation and mineralization. The 57-kDa C-terminal
fragment also plays a key role in maintaining phosphate
homeostasis through regulating Fgf23 expression in bone. The
37-kDa N-terminal fragment is a proteoglycan.
(18) It may function
as a propeptide but has little, if any, role in osteocyte maturation
and bone mineralization. This is supported by the observation
that human patients with DMP1 mutations in the C-terminal end
of DMP-1 still suffer from ARHR even though they have normal
37-kDa N-terminal expression.
(6) Our current findings suggest
thatsmallsyntheticpeptidesintheC-terminusofDMP-1(suchas
ASARM) could be developed for clinical treatment of hypopho-
sphatemic disorders in the future.
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